[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054149":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":253,"collaborators":255,"id":258,"slug":24,"hasResults":259,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":259,"sex":265,"minAge":266,"maxAge":24,"enrollmentInfo":267,"targetDuration":24,"studyType":270,"phases":271,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Module 1 Dose Escalation","EXPERIMENTAL","Module 1 will evaluate escalating doses of AZD4512 as monotherapy to determine the maximum tolerated dose (MTD) and\u002For doses of AZD4512 for subsequent evaluation in Module 2 (dose optimization), in participants with relapsed\u002Frefractory (R\u002FR) Philadelphia chromosome positive (Ph\\[+\\]) and negative (Ph\\[-\\]) B-ALL, R\u002FR as defined by National Comprehensive Cancer Network (NCCN) guidelines.",[13],"Combination Product: AZD4512 monotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Module 2 Dose Optimization","Module 2 will randomize participants with R\u002FR (as defined by NCCN guidelines) Ph(-) BALL only across 2 to 3 dose levels identified in Module 1 to receive AZD4512 monotherapy for further exploration of the doses. The aim of Module 2 is to identify the recommended Phase 2 dose (RP2D) of AZD4512 monotherapy, evaluate the efficacy and further define the safety profile of AZD4512.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"COMBINATION_PRODUCT","AZD4512 monotherapy","Patients will receive AZD4512 as monotherapy via intravenous infusion. AZD4512 is an antibody-drug conjugate targeting CD22",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[32,45,55,64,73,82,91,100,111,120,129,137,146,154,163,168,173,178,187,195,203,211,219,228,236,245],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":24},"Research Site","RECRUITING","Duarte","California","91010","United States",{"type":40,"coordinates":41},"Point",[42,43],-117.97729,34.13945,{"lat":43,"lon":42},{"facility":33,"status":46,"city":47,"state":48,"zip":49,"country":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":24},"WITHDRAWN","Jacksonville","Florida","32224",{"type":40,"coordinates":51},[52,53],-81.65565,30.33218,{"lat":53,"lon":52},{"facility":33,"status":34,"city":56,"state":57,"zip":58,"country":38,"cosmosGeoPoint":59,"geoPoint":63,"contacts":24},"Chicago","Illinois","60611",{"type":40,"coordinates":60},[61,62],-87.65005,41.85003,{"lat":62,"lon":61},{"facility":33,"status":34,"city":65,"state":66,"zip":67,"country":38,"cosmosGeoPoint":68,"geoPoint":72,"contacts":24},"Iowa City","Iowa","52242",{"type":40,"coordinates":69},[70,71],-91.53017,41.66113,{"lat":71,"lon":70},{"facility":33,"status":34,"city":74,"state":75,"zip":76,"country":38,"cosmosGeoPoint":77,"geoPoint":81,"contacts":24},"Franklin","Tennessee","37067",{"type":40,"coordinates":78},[79,80],-86.86889,35.92506,{"lat":80,"lon":79},{"facility":33,"status":34,"city":83,"state":84,"zip":85,"country":38,"cosmosGeoPoint":86,"geoPoint":90,"contacts":24},"Houston","Texas","77030",{"type":40,"coordinates":87},[88,89],-95.36327,29.76328,{"lat":89,"lon":88},{"facility":33,"status":34,"city":92,"state":24,"zip":93,"country":94,"cosmosGeoPoint":95,"geoPoint":99,"contacts":24},"Melbourne","3000","Australia",{"type":40,"coordinates":96},[97,98],144.96332,-37.814,{"lat":98,"lon":97},{"facility":33,"status":101,"city":102,"state":103,"zip":104,"country":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":24},"NOT_YET_RECRUITING","Vancouver","British Columbia","V5Z 1M9","Canada",{"type":40,"coordinates":107},[108,109],-123.11934,49.24966,{"lat":109,"lon":108},{"facility":33,"status":34,"city":112,"state":113,"zip":114,"country":105,"cosmosGeoPoint":115,"geoPoint":119,"contacts":24},"Toronto","Ontario","M5G 1X6",{"type":40,"coordinates":116},[117,118],-79.39864,43.70643,{"lat":118,"lon":117},{"facility":33,"status":101,"city":121,"state":24,"zip":122,"country":123,"cosmosGeoPoint":124,"geoPoint":128,"contacts":24},"Guangzhou","510515","China",{"type":40,"coordinates":125},[126,127],113.25,23.11667,{"lat":127,"lon":126},{"facility":33,"status":101,"city":130,"state":24,"zip":131,"country":123,"cosmosGeoPoint":132,"geoPoint":136,"contacts":24},"Tianjin","301600",{"type":40,"coordinates":133},[134,135],117.17667,39.14222,{"lat":135,"lon":134},{"facility":33,"status":34,"city":138,"state":24,"zip":139,"country":140,"cosmosGeoPoint":141,"geoPoint":145,"contacts":24},"Bunkyō City","113-8677","Japan",{"type":40,"coordinates":142},[143,144],139.4217,35.5331,{"lat":144,"lon":143},{"facility":33,"status":34,"city":147,"state":24,"zip":148,"country":140,"cosmosGeoPoint":149,"geoPoint":153,"contacts":24},"Chūōku","104-0045",{"type":40,"coordinates":150},[151,152],130.67068,33.63867,{"lat":152,"lon":151},{"facility":33,"status":34,"city":155,"state":24,"zip":156,"country":157,"cosmosGeoPoint":158,"geoPoint":162,"contacts":24},"Seoul","03080","South Korea",{"type":40,"coordinates":159},[160,161],126.9784,37.566,{"lat":161,"lon":160},{"facility":33,"status":34,"city":155,"state":24,"zip":164,"country":157,"cosmosGeoPoint":165,"geoPoint":167,"contacts":24},"06351",{"type":40,"coordinates":166},[160,161],{"lat":161,"lon":160},{"facility":33,"status":34,"city":155,"state":24,"zip":169,"country":157,"cosmosGeoPoint":170,"geoPoint":172,"contacts":24},"06591",{"type":40,"coordinates":171},[160,161],{"lat":161,"lon":160},{"facility":33,"status":34,"city":155,"state":24,"zip":174,"country":157,"cosmosGeoPoint":175,"geoPoint":177,"contacts":24},"3722",{"type":40,"coordinates":176},[160,161],{"lat":161,"lon":160},{"facility":33,"status":101,"city":179,"state":24,"zip":180,"country":181,"cosmosGeoPoint":182,"geoPoint":186,"contacts":24},"Badalona(Barcelona)","08916","Spain",{"type":40,"coordinates":183},[184,185],2.24741,41.45004,{"lat":185,"lon":184},{"facility":33,"status":34,"city":188,"state":24,"zip":189,"country":181,"cosmosGeoPoint":190,"geoPoint":194,"contacts":24},"Barcelona","08035",{"type":40,"coordinates":191},[192,193],2.15899,41.38879,{"lat":193,"lon":192},{"facility":33,"status":34,"city":196,"state":24,"zip":197,"country":181,"cosmosGeoPoint":198,"geoPoint":202,"contacts":24},"Salamanca","37007",{"type":40,"coordinates":199},[200,201],-5.66388,40.96882,{"lat":201,"lon":200},{"facility":33,"status":34,"city":204,"state":24,"zip":205,"country":181,"cosmosGeoPoint":206,"geoPoint":210,"contacts":24},"Santander","39008",{"type":40,"coordinates":207},[208,209],-3.80493,43.46589,{"lat":209,"lon":208},{"facility":33,"status":46,"city":212,"state":24,"zip":213,"country":181,"cosmosGeoPoint":214,"geoPoint":218,"contacts":24},"Valencia","46026",{"type":40,"coordinates":215},[216,217],-0.37966,39.47391,{"lat":217,"lon":216},{"facility":33,"status":34,"city":220,"state":24,"zip":221,"country":222,"cosmosGeoPoint":223,"geoPoint":227,"contacts":24},"Taichung","40705","Taiwan",{"type":40,"coordinates":224},[225,226],120.6839,24.1469,{"lat":226,"lon":225},{"facility":33,"status":34,"city":229,"state":24,"zip":230,"country":222,"cosmosGeoPoint":231,"geoPoint":235,"contacts":24},"Taipei","106",{"type":40,"coordinates":232},[233,234],121.52639,25.05306,{"lat":234,"lon":233},{"facility":33,"status":34,"city":237,"state":24,"zip":238,"country":239,"cosmosGeoPoint":240,"geoPoint":244,"contacts":24},"Bloomsbury","W1T 7HA","United Kingdom",{"type":40,"coordinates":241},[242,243],-0.12252,51.52228,{"lat":243,"lon":242},{"facility":33,"status":34,"city":246,"state":24,"zip":247,"country":239,"cosmosGeoPoint":248,"geoPoint":252,"contacts":24},"Manchester","M20 4BX",{"type":40,"coordinates":249},[250,251],-2.23743,53.48095,{"lat":251,"lon":250},{"type":254,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[256],{"name":257,"class":6},"Fortrea","100054149",false,"NCT07109219","Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","A Modular Phase I\u002FII, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia","ALLight","Inclusion Criteria:\n\n* 1\\. Age:\n\n  * 16 years old in Module 1 (US only: ≥18year)\n  * 12 years old in Module 2\n\n    2\\. Diagnosis: Known Diagnosis of CD22-positive B-ALL based on criteria established by WHO (Alaggio et al. 2022).\n* Participants must have relapsed or refractory B-ALL ('relapsed' defined as bone marrow blasts \\> 5% or reappearance of blasts in PB)\n* Module 1 (DE): Ph(-) B-ALL and Ph(+) B-ALL - R\u002FR\n* Backfill of Module 1 and Module 2 (DO): R\u002FR Ph(-) B-ALL\n\n  3\\. Performance status (ECOG ≤ 2; KPS ≥ 50; LPS ≥ 50)\n\n  4\\. Peripheral lymphoblast count \\\u003C 10,000\u002FµL (may receive cytoreduction prior to C1D1 per protocol-specified criteria)\n\n  5\\. At least 2 prior therapies with refractoriness or relapse, or 1 prior therapy with refractoriness or relapse and no standard options available. Participants who have received prior CD22 targeted therapies are eligible.\n* Ph+ B-ALL (Module 1 DE only): intolerant to or have contraindications to TKI therapy or R\u002FR disease despite treatment with at least 2 prior TKIs or at least one 3rd generation TKI\n\n  6\\. Prior DLI \\>4 weeks, prior cell therapy or autoHSCT \\>8 weeks, alloHSCT \\>12 weeks\n\nExclusion Criteria:\n\n1. Burkitt lymphoma and leukemia\n2. Isolated extramedullary disease; Active testicular or CNS (\\> CNS1) involvement\n3. Unresolved non-heme toxicities Grade ≥ 2 (except alopecia, stable Grade ≤ 2 neuropathy, vitiligo, endocrine disorders controlled with therapy)\n4. History of drug-induced non-infectious ILD\u002Fpneumonitis requiring oral or IV steroids or supplemental oxygen or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n5. Prior\u002Fconcomitant therapy\n\n   * Cytotoxic treatment within 14 days (except ALL maintenance medications or cytoreduction)\n   * Biologic (immuno-oncology) treatment within 28 days or 5 half-lives (whichever is shorter)\n   * Non-CNS radiation within 2 weeks \\& CNS radiation within 4 weeks\n   * Medications known to prolong QTc and\u002For associated with Torsades de Pointes within 5 half-lives\n   * Strong inhibitors of CYP 3A4 within 14 days or 5 half-lives (whichever is longer)\n   * Investigational agents or study interventions in the last 30 days or 5 half-lives prior to the first dose of AZD4512 whichever is longer. If the investigational product is an agent to treat B-ALL and meets the modality criteria, then a specific washout period must be adhered to instead.","ALL","12 Years",{"count":268,"type":269},83,"ESTIMATED","INTERVENTIONAL",[272,273],"PHASE1","PHASE2","The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed\u002Frefractory B-Cell acute lymphoblastic leukemia (r\u002Fr B-ALL).",[276],"B-cell Acute Lymphoblastic Leukemia (B-ALL)",[278,279,280,281,282],"Acute lymphoblastic leukemia (B-ALL)","Dose escalation","Dose optimization","Cluster of differentiation 22 (CD22)","Antibody-drug conjugate (ADC)","2026-07-10",{"date":285,"type":286},"2026-07-13","ACTUAL",{"date":288,"type":286},"2025-11-12",{"date":290,"type":269},"2028-07-03",{"name":5,"class":6},26]